<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T17:15:28Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/s5nb3bxyjf.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/s5nb3bxyjf.1</identifier>
                <datestamp>2020-10-26T16:09:28Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>fan, zhang</dc:creator>
    <dc:title>Data for: In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution proﬁles using PBPK modeling and simulation</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>The research data files are compromise of 5 supplementary materials.  The detailed information of clinical study is displayed in Supplementary material 1, and all simulated data in manuscript are shown in supplementary material 2-5:
1) supplementary material 1 (the detailed information of clinical study)   
2) supplementary material 2 (the simulated data used for internal verification of PBPK model) 
3) supplementary material 3 (the simulated data used for external verification of PBPK model)    
4) supplementary material 4 (the simulated data used in the section 4.3 of manuscript) : this simulated data was used  to explore whether the rapid dissolution rate (dissolved ≥ 85% in 30 min) are necessary to ensure the bioequivalence for BCS I class drug
5) supplementary material 5 (the simulated data used in the section 4.4 of manuscript) : this simulated data was used  to establish a clinically relevant dissolution specification of Isosorbide Mononitrate tablets.
</dc:description>
    <dc:subject>Pharmacokinetics</dc:subject>
    <dc:subject>Pharmacokinetic Modeling</dc:subject>
    <dc:subject>Bioequivalence</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/s5nb3bxyjf.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/s5nb3bxyjf.1</dc:identifier>
    <dc:rights>Public Domain Dedication</dc:rights>
    <dc:rights>http://creativecommons.org/publicdomain/zero/1.0/</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/s5nb3bxyjf</dc:relation>
    <dc:date>2020-10-26T16:09:28Z</dc:date>
    <dc:date>2021-08-07T00:00:00Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
